Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Soligenix ($SNGX) stock buoyed as the company prepares to present the data for RiVax, its ricin toxin vaccine. The company will present the data at the 20th Annual Conference on Vaccine Research in Bethesda, MD. RiVax demonstrated 100% protection in ricin aerosol challenge models during its preclinical testing. The drug has been formulated with the company's ThermoVax heat stabilization.
Soligenix said that the data should support the FDA approval of RiVax under the "Animal Rule" which allows regulatory approval of certain drugs and biologics based on animal testing in situations where human testing is not possible or ethical. The company stock is up 64 percent this year so far.

ContraVir Pharmaceuticals ($CTRV) shot up as the company announced positive results from a Phase 2a clinical trial assessing tenofovir exalidex (TXL) in patients with chronic hepatitis B virus (HBV) infection. Preliminary results showed treatment with TXL for 21 days resulted in a mean HBV viral load of 3,630 copies/mL compared to a mean viral load of 3,750 copies/mL for Gilead Sciences' Viread (tenofovir disoproxil fumarate). The results also suggested that there were no serious adverse events (SAEs) observed and no discontinuations due to AEs.
The stock reacted positively to the news and gained over 14 percent in the pre-market session. The stock is on robust ground as it gained over 34 percent this year so far.

 

UniQure ($QURE) announced that it will not opt for renewing its European marketing authorization for Glybera (alipogene tiparvovec). The current authorization is set to expire on October 25. The treatment was approved in 2012 for treating an ultra-rare condition called lipoprotein lipase deficiency. The company cited lack of demand as the reason for its decision.

AbbVie ($ABBV) announced that two Phase 3 clinical trials evaluating its PARP inhibitor veliparib, in combination with chemo, failed to meet the primary endpoints. The first study had 970 subjects and failed to meet the endpoint of overall survival in the group who has smoked withing the past 12 months and had more than 100 smoking events in their lifetime. Other study evaluated the effect of adding veliparib to carboplatin and standard neoadjuvant chemo (paclitaxel) in patients with early-stage triple-negative breast cancer.

Tesaro ($TSRO) announced the launch of its  PARP inhibitor ZEJULA (niraparib) in the US market. The treatment is designed as the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who have completely or partially responded to platinum-based chemo. It was approved by the FDA in March this year.

ANI Pharmaceuticals ($ANIP) announced the launch of its generic version of indapamide tablets. These tablets are used for treating hypertension and swelling associated with congestive heart failure.

 

Novelion Therapeutics ($NVLN) announced receiving approval from the Toronto Stock Exchange for its request to delist effective at the market close on May 3. The company took the decision due to low trading volume on the exchange. The stock will keep trading on the Nasdaq Global Select Market.

NuVasive ($NUVA) announced the commercial launch of its RELINE Trauma system, a portfolio of products targeted to the spine trauma fixation market. The system lets the surgeons customize their approach during surgery, including open, maximum access surgery (MAS) or hybrid procedures. 

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Morgan Stanley
Downgrades
NanoString Technologies (NSTG)
Overweight -> Equal Weight
$18.99 -> $20.00
Low
JPMorgan Chase & Co.
Downgrades
ResMed (RMD)
Overweight -> Neutral

Low
JPMorgan Chase & Co.
Reiterates
Sanofi SA (SNY)
Neutral

Low
BTIG Research
Reiterates
Intuitive Surgical (ISRG)
Hold

Low

Gainers (% price change) Last Trade Change Mkt Cap
NewLink Genetics Corp NLNK 19.02 +3.02 (18.88%) 558.89M
Rockwell Medical Inc RMTI 7.85 +0.85 (12.14%) 428.36M
ImmunoGen, Inc. IMGN 3.58 +0.34 (10.49%) 318.63M
Accelerate Diagnostics AXDX 25.15 +1.70 (7.25%) 1.31B
Intuitive Surgical, Inc. ISRG 807.70 +48.36 (6.37%) 29.32B
Losers (% price change)
Immunomedics, Inc. IMMU 5.80 -0.57 (-8.95%) 615.26M
Rigel Pharmaceuticals RIGL 3.05 -0.24 (-7.29%) 387.09M
Corcept Therapeutics Inc. CORT 10.08 -0.74 (-6.84%) 1.09B
Compugen Ltd. (USA) CGEN 3.95 -0.15 (-3.66%) 197.01M
Clovis Oncology Inc CLVS 54.44 -1.69 (-3.01%) 2.38B
Most Actives (dollar volume)
Intuitive Surgical, Inc. ISRG 807.70 +48.36 (6.37%) 29.32B
Johnson & Johnson JNJ 121.37 -0.45 (-0.37%) 318.81B
UnitedHealth Group Inc UNH 169.25 +0.66 (0.39%) 164.60B
Pfizer Inc. PFE 33.61 -0.23 (-0.68%) 199.21B
Merck & Co., Inc. MRK 62.64 +0.37 (0.59%) 171.21B